Centene Corporation

NYSE:CNC 주식 리포트

시가총액: US$28.8b

Centene 향후 성장

Future 기준 점검 3/6

Centene (는) 각각 연간 66.9% 및 3.6% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 65.2% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 9.5% 로 예상됩니다.

핵심 정보

66.9%

이익 성장률

65.24%

EPS 성장률

Healthcare 이익 성장18.3%
매출 성장률3.6%
향후 자기자본이익률9.53%
애널리스트 커버리지

Good

마지막 업데이트21 May 2026

최근 향후 성장 업데이트

Recent updates

내러티브 업데이트 • May 16

CNC: Margin Recovery Efforts Will Offset Policy And Exchange Uncertainty

Centene's updated analyst price target moves from $43.47 to $54.94 as analysts factor in slightly higher revenue growth assumptions, a higher forward P/E multiple, and recent price target increases and upgrades across several research firms, balanced by some ongoing margin concerns. Analyst Commentary Recent research updates on Centene show a mix of optimism on the earnings and margin recovery path alongside caution about Medicaid and exchange exposure.
내러티브 업데이트 • Apr 29

CNC: Policy And Exchange Uncertainty Will Pressure Margins And Constrain Upside

Analysts have trimmed the fair value estimate for Centene to $43.47 from $44.18, reflecting updated views on revenue growth, margin potential, and a lower expected future P/E multiple, even as several recent price target revisions highlight ongoing debate around the stock. Analyst Commentary Recent Street research paints a mixed picture for Centene, with several firms adjusting price targets and ratings as they reassess the company after Q4 results, updated guidance, and regulatory developments.
Seeking Alpha • Apr 28

Centene: Big Comeback Story

Summary Centene Corporation delivered a strong Q1 earnings beat, signaling a robust turnaround after a challenging year for health insurers. Q1 revenue surged to $49.94 billion, up 7.1% year-over-year and $2.4 billion above consensus, driven by premium yield and Medicaid growth. Cost discipline was evident as the health benefits ratio fell to 87.3% and SG&A expenses declined, fueling a $1.24 adjusted EPS beat versus consensus. CNC raised 2026 revenue and EPS guidance, now projecting at least $3.40 adjusted EPS—a 63.4% year-over-year increase—supporting a bullish re-rating and buy recommendation. Read the full article on Seeking Alpha
내러티브 업데이트 • Apr 15

CNC: Medicaid Margins In 2026 Will Underpin Future Earnings Power

Centene's updated analyst price targets show only a modest reduction in implied fair value to about $60.51, as analysts factor in slightly better revenue growth and margins while tempering expectations with lower assumed P/E multiples and continued concern about margin pressure and exchange and Medicaid visibility. Analyst Commentary Recent research on Centene points to a mixed backdrop, but with a clear group of bullish analysts highlighting valuation support, execution on margins, and potential growth from policy and rate decisions.
내러티브 업데이트 • Apr 01

CNC: Government Program Margins In 2026 Will Support Future Earnings Power

Centene's updated analyst price targets show a modest downward reset of about $4 across several firms to a range of roughly $32 to $49, with analysts citing recalibrated valuation multiples, ongoing Medicaid and exchange visibility questions, and mixed readthroughs from recent Q4 results and policy headlines. Analyst Commentary Recent research shows a split view on Centene, with some firms trimming targets and others lifting them, but the common thread is a focus on how Medicaid, exchange membership, and Q4 execution shape the risk and reward profile from here.
내러티브 업데이트 • Mar 18

CNC: Government Managed Care Recovery In 2026 Will Support Future Earnings Power

Narrative Update Centene's implied fair value estimate has edged lower to about $60.89 from $62.81 as analysts recalibrated price targets. This reflects slightly softer growth and margin assumptions and a mix of recent target cuts and trims in valuation multiples across the group.
내러티브 업데이트 • Mar 04

CNC: Medicaid And Exchange Uncertainty Will Pressure Margins Despite 2026 EPS Guidance

Analysts have nudged their average price targets for Centene higher into a $43 to $59 range, pointing to margin improvement efforts, potential earnings power across segments, and sector recovery themes, even as they flag ongoing uncertainty around Medicaid and exchange visibility. Analyst Commentary Recent research on Centene shows a mix of optimism around margin potential and earnings power, alongside pointed concerns about execution risks in key government programs.
내러티브 업데이트 • Feb 17

CNC: Policy Uncertainty And Margin Recovery Prospects Will Shape Balanced Outlook

Analysts have lifted their average price target on Centene by about $3 to roughly $44, citing updated views on fair value, slightly higher expected profit margins and P/E, and ongoing research that points to potential margin recovery in government managed care despite recent CMS related concerns. Analyst Commentary Recent research on Centene reflects a mix of optimism around long term earnings power in government managed care and caution around policy and utilization risks that could affect how quickly that potential is realized.
내러티브 업데이트 • Feb 03

CNC: CMS Rate Pressure And Medicaid Uncertainty Will Restrain Future Earnings Recovery

Analysts have lifted their price targets on Centene into a US$43 to US$59 range, citing updated views on government managed care earnings potential and recently softer utilization trends, even as broader commentary highlights ongoing policy and Medicaid uncertainty for the sector. Analyst Commentary Recent research on Centene sits against a mixed backdrop for government managed care, with several firms highlighting both potential earnings recovery drivers and ongoing policy and contract risks.
내러티브 업데이트 • Jan 20

CNC: Government Managed Care Policy Tailwinds Will Support Future Earnings Power

Analysts have lifted their fair value estimate for Centene from about $54.65 to roughly $62.81, citing updated views on discount rates, revenue growth, margins, and future P/E following recent price target hikes and sector commentary around government managed care and the "Great Healthcare Plan." Analyst Commentary Bullish analysts are highlighting a mix of policy tailwinds, product positioning, and company specific execution as reasons to revisit Centene's valuation. Recent research focuses on how government managed care, Medicare Advantage rate discussions, and the "Great Healthcare Plan" could influence earnings power and the multiple investors are willing to pay.
내러티브 업데이트 • Jan 06

CNC: Marketplace Margin Recovery And Medicaid Pressures Will Shape Balanced Outlook

Analysts have raised their implied fair value estimate for Centene to about US$41 from roughly US$40, reflecting a mix of higher price targets tied to recent earnings beats and margin recovery expectations in Marketplace and Medicaid, partially balanced by concerns around Medicaid trends and contract losses. Analyst Commentary Recent Street research on Centene reflects a split view, with some analysts focusing on earnings power from margin recovery and others highlighting ongoing risks in Medicaid and selected contracts.
내러티브 업데이트 • Dec 19

CNC: Medicaid Margin Pressures Will Likely Cap Earnings Recovery Ahead

Analysts have raised their fair value estimate for Centene to $32 from $24, citing improving margin visibility, stronger than expected Q3 results, and a more constructive long term earnings trajectory despite near term Medicaid and contract headwinds. Analyst Commentary Street research following Centene's Q3 earnings has been mixed, with several firms lifting price targets on the back of stronger profitability trends while others caution that EPS visibility remains constrained by Medicaid and Marketplace uncertainties.
내러티브 업데이트 • Dec 05

CNC: Marketplace And Medicaid Margin Normalization Will Offset Policy And Contract Headwinds

Analysts have modestly raised their price target on Centene to $39.94 from $39.41, citing improved profit margin visibility and expectations for continued EPS growth as Marketplace and Medicaid margins recover, despite lingering near-term Medicaid pressures. Analyst Commentary Street research on Centene has become more polarized, with several bullish analysts lifting price targets into the mid 40s on the back of Q3 outperformance and clearer earnings visibility, while a cohort of more cautious voices highlight lingering Medicaid and Star rating risks that could constrain valuation multiple expansion.
내러티브 업데이트 • Nov 21

CNC: Margin Recovery In Medicaid And Marketplace Will Drive 2026 Earnings Upside

Centene's analyst price target has increased by $5.59 to $45.00, as analysts expect margin recovery in the Marketplace and Medicaid segments to drive accelerated earnings growth, despite ongoing near-term pressures. Analyst Commentary Recent research coverage of Centene highlights a mix of positive and negative outlooks, with analyst views divided over the company’s near- and medium-term trajectory.
내러티브 업데이트 • Nov 06

CNC: Medicaid Margin Stability And 26% ACA Premium Hike Will Shape 2026 Prospects

Centene’s analyst price target has been raised from $36 to approximately $39.76 per share. Analysts cite improving Medicaid profitability and stronger earnings guidance as key drivers for the upward revision.
내러티브 업데이트 • Oct 22

Analysts Lift Centene Price Target on Margin Recovery but Warn of Lasting Sector Headwinds

Centene's analyst fair value target has been increased from $34.63 to $36.00. Analysts highlight improving margin visibility and constructive EPS guidance updates as key factors supporting the upward revision.
내러티브 업데이트 • Oct 08

Medicaid And Medicare Advantage Will Expand Health Care Access

Centene's analyst price target increased from $33.94 to $34.63, as analysts cited stable EPS guidance, anticipated Medicaid margin improvement, and a constructive outlook for Marketplace rates as supporting factors for the revision. Analyst Commentary Recent analyst research on Centene reflects a full spectrum of perspectives, as experts weigh strong execution signals against ongoing uncertainties in the managed care and healthcare exchange landscape.
내러티브 업데이트 • Sep 19

Medicaid And Medicare Advantage Will Expand Health Care Access

Centene's modest price target increase reflects mixed analyst sentiment, with optimism around reaffirmed FY25 EPS guidance and Medicaid margin improvements tempered by concerns over ongoing Medicaid and marketplace pressures, regulatory risks, and reduced long-term earnings visibility, resulting in a slight upward revision of fair value to $33.94. Analyst Commentary Bullish analysts cite reaffirmation of FY25 adjusted EPS guidance and constructive commentary on Medicaid margin improvement, ACA Marketplace rate refiling, and Stars performance as supporting recent price target raises.
분석 기사 • Sep 12

Centene Corporation's (NYSE:CNC) Price Is Right But Growth Is Lacking After Shares Rocket 30%

Centene Corporation ( NYSE:CNC ) shareholders are no doubt pleased to see that the share price has bounced 30% in the...
내러티브 업데이트 • Sep 04

Medicaid And Medicare Advantage Will Expand Health Care Access

Centene’s analyst price target remains at $34.56 as ongoing macro and regulatory uncertainty, elevated Medicaid cost trends, and withdrawn 2025 EPS guidance have driven increased caution and reduced forward earnings visibility. Analyst Commentary Persistent macro uncertainty and regulatory volatility in the healthcare exchange (ACA Marketplace) and Medicaid markets are driving cautious outlooks, especially due to potential disenrollment, risk pool degradation, and rate/trend volatility stemming from legislative changes and the expiration of enhanced APTCs. Centene’s withdrawal of FY2025 EPS guidance, prompted by incorrect Marketplace risk-adjustment assumptions and elevated Medicaid cost trends, has resulted in significant downward revisions to earnings estimates for the next three years.
분석 기사 • Jul 03

Why Investors Shouldn't Be Surprised By Centene Corporation's (NYSE:CNC) 38% Share Price Plunge

Unfortunately for some shareholders, the Centene Corporation ( NYSE:CNC ) share price has dived 38% in the last thirty...
Seeking Alpha • Mar 26

Centene: A Leader In Government-Sponsored Insurance And Its Prospects

Summary Centene's business transformation and strategic focus on core segments have led to increased operational marginality, despite losing 3.3 million Medicaid customers in 2024. I assign a "Buy" rating to Centene, with a fair valuation of $73 per share, indicating a 27% potential increase from the current price. The company’s competitive advantage lies in its focus on Medicaid and Medicare, but it faces risks from regulatory changes and strong competition. Centene's prospects are bolstered by demographic trends, Medicaid privatization, and ACA Marketplace demand, with expected improvements in cash flow and profitability. Read the full article on Seeking Alpha
Seeking Alpha • Mar 18

Centene Corporation Is Resilient And Will Thrive

Summary Centene Corporation is a buy opportunity under $60, with a strong valuation and momentum, despite market volatility and economic concerns. The company reported strong Q4 '24 results, with EPS of $0.80 and FY '24 EPS of $7.17, and management raised 2025 revenue guidance by $4 billion. Risks include potential Medicaid and Medicare enrollment cuts, program pullbacks, and cash flow concerns for the company, but we expect management to navigate these challenges. Insiders and hedge funds are investing, indicating confidence in Centene's resilience and growth potential, with a target price of around $72. Read the full article on Seeking Alpha
Seeking Alpha • Jan 02

Centene: Attractive Risk-Reward For A Growing Company At A Value Price

Summary Centene reported strong Q3’24 results, beating revenue expectations by $4.13 billion and achieving EPS of $1.62, driven by Medicaid rate increases and membership growth. Key highlights from the quarter include successful Medicaid reprocurements, improved 2025 Medicare Advantage star ratings, and advancements in AI for operational efficiency, positioning Centene for long-term growth. Despite some leverage, Centene's investment-grade rating and attractive debt maturities suggest financial stability, with a promising outlook for EPS growth and Medicare revenue. Insider buying and undervaluation, with Centene trading at around 10x earnings, indicate confidence in the company's future despite Medicaid redetermination and regulatory risks. Read the full article on Seeking Alpha
Seeking Alpha • Oct 22

Centene: Should Have Followed My Original Thesis, But A Buy For Q3 2024

Summary Centene, a leading health insurer, shows strong fundamentals and growth despite sector challenges, making it a "Buy" at a target price of $70/share. The company’s 2Q24 results indicate robust earnings growth and increasing membership, contrasting with peers like Humana, which face significant declines. Centene's valuation at $61/share with a P/E of 9x is attractive, projecting a potential 27.17% annualized upside until 2026. Despite lacking a dividend, Centene's stability and growth prospects in government programs and managed healthcare segments justify a conservative investment approach. Read the full article on Seeking Alpha

이익 및 매출 성장 예측

NYSE:CNC - 애널리스트 향후 추정치 및 과거 재무 데이터 (USD Millions)
날짜매출이익자유현금흐름영업현금흐름평균 애널리스트 수
12/31/2028197,9022,4862,5463,93511
12/31/2027190,8591,6361,6072,72014
12/31/2026190,3751,2222,7474,16414
3/31/2026178,332-6,4447,1127,944N/A
12/31/2025176,151-6,6744,3215,088N/A
9/30/2025167,285-5,2903,3564,064N/A
6/30/2025159,2682,0541,0801,730N/A
3/31/2025153,2443,4531,4922,120N/A
12/31/2024147,1453,305-490154N/A
9/30/2024146,3523,067245958N/A
6/30/2024144,2022,8232,2612,957N/A
3/31/2024142,9492,7352,6033,328N/A
12/31/2023141,3932,7027,2548,053N/A
9/30/2023139,3642,4445,4516,260N/A
6/30/2023138,1112,7137,6518,571N/A
3/31/2023136,9411,4838,3929,379N/A
12/31/2022135,9991,2025,2576,261N/A
9/30/2022132,7562,0147,4938,512N/A
6/30/2022129,2281,8605,9856,982N/A
3/31/2022124,1811,4974,3485,313N/A
12/31/2021118,5731,3473,2954,205N/A
9/30/2021114,1307365,6436,511N/A
6/30/2021111,2847202,8633,757N/A
3/31/2021108,1582,4614,9075,786N/A
12/31/2020104,2801,8084,6345,503N/A
9/30/202095,7642,0291,0081,871N/A
6/30/202086,5231,5561,9182,724N/A
3/31/202078,105845-804-73N/A
12/31/201970,8071,321N/A1,483N/A
9/30/201968,3851,353N/A1,500N/A
6/30/201965,5071,277N/A2,147N/A
3/31/201961,0281,082N/A704N/A
12/31/201856,688900N/A1,234N/A
9/30/201852,618889N/A2,318N/A
6/30/201848,6551,075N/A1,867N/A
3/31/201847,2011,029N/A2,087N/A
12/31/201745,810828N/A1,489N/A
9/30/201744,870853N/A2,631N/A
6/30/201743,646796N/A3,016N/A
3/31/201742,468713N/A2,903N/A
12/31/201637,693562N/A1,851N/A
9/30/201632,839416N/A460N/A
6/30/201628,062360N/A40N/A
3/31/201622,948277N/A809N/A
12/31/201521,292356N/A658N/A
9/30/201519,854350N/A827N/A
6/30/201518,548339N/A1,206N/A

애널리스트 향후 성장 전망

수입 대 저축률: CNC 은 향후 3년 동안 수익을 낼 것으로 예상되며, 이는 절약률(3.5%)보다 빠른 성장으로 간주됩니다.

수익 vs 시장: CNC (는) 향후 3년 동안 평균 시장 성장보다 높은 수익을 올릴 것으로 예상됩니다.

고성장 수익: CNC 향후 3년 내에 수익을 낼 것으로 예상됩니다.

수익 대 시장: CNC 의 수익(연간 3.6%)이 US 시장(연간 11.6%)보다 느리게 성장할 것으로 예상됩니다.

고성장 매출: CNC 의 수익(연간 3.6%)은 연간 20%보다 느리게 증가할 것으로 예상됩니다.

주당순이익 성장 예측

향후 자기자본이익률

미래 ROE: CNC의 자본 수익률은 3년 후 9.5%로 낮을 것으로 예상됩니다.

성장 기업 찾아보기

7D

1Y

7D

1Y

7D

1Y

기업 분석 및 재무 데이터 상태

데이터최종 업데이트 (UTC 시간)
기업 분석2026/05/21 21:51
종가2026/05/21 00:00
수익2026/03/31
연간 수익2025/12/31

데이터 소스

당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.

패키지데이터기간미국 소스 예시 *
기업 재무제표10년
  • 손익계산서
  • 현금흐름표
  • 대차대조표
분석가 컨센서스 추정치+3년
  • 재무 예측
  • 분석가 목표주가
시장 가격30년
  • 주가
  • 배당, 분할 및 기타 조치
지분 구조10년
  • 주요 주주
  • 내부자 거래
경영진10년
  • 리더십 팀
  • 이사회
주요 개발10년
  • 회사 공시

* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.

별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.

분석 모델 및 스노우플레이크

이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.

Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.

산업 및 섹터 지표

산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.

분석가 소스

Centene Corporation는 34명의 분석가가 다루고 있습니다. 이 중 14명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.

분석가기관
null nullArgus Research Company
Hua HaBaird
Andrew MokBarclays